Cishe-umdlavuza / ukwelashwa / ukuhlolwa kwezilingo / izifo / umdlavuza / anal-cancer / ukwelashwa

Ukwelashwa Izivivinyo Zomtholampilo Womdlavuza Wama-Anal

Ukuhlolwa kwemitholampilo kuyizifundo zocwaningo ezibandakanya abantu. Ukuhlolwa kwemitholampilo kulolu hlu kungokwelashwa komdlavuza wesitho sangasese. Zonke izilingo ohlwini zisekelwa yi-NCI.

Imininingwane eyisisekelo ye-NCI mayelana nokuhlolwa komtholampilo ichaza izinhlobo nezigaba zezilingo nokuthi zenziwa kanjani. Ukuhlolwa komtholampilo kubheka izindlela ezintsha zokuvimbela, ukuthola, noma ukwelapha izifo. Ungahle uthande ukucabanga ngokubamba iqhaza esivivinyweni somtholampilo. Khuluma nodokotela wakho ngosizo lokunquma ukuthi ngabe kukulungele yini.

Izilingo 1-23 kwezingu-23

INivolumab ngemuva Kokwelashwa Kwemodi Ehlanganisiwe Ekwelapheni Iziguli Ezinengozi Ephakeme Yobungozi II-IIIB Cancer

Lesi sigaba sokuhlolwa komtholampilo sesigaba II esingahleliwe sihlola ukuthi i-nivolumab ngemuva kokwelapha okuhlanganisiwe isebenza kanjani ekwelapheni iziguli ezinesifo esinomdlavuza omkhulu wesigaba II-IIIB. I-Immunotherapy enama-antibody monoclonal, njenge-nivolumab, ingasiza amasosha omzimba ukuthi ahlasele umdlavuza, futhi ingaphazamisa amandla amangqamuzana e-tumor ukuthi akhule futhi asabalale.

Indawo: izindawo ezingama-744

I-Nivolumab ene-Ipilimumab noma engenayo ekwelapheni iziguli ezine-Refractory Metastatic Anal Canal Cancer

Lesi sigaba sesivivinyo sesi-II sihlola ukuthi i-nivolumab isebenza kanjani noma ingenayo i-ipilimumab ekwelapheni iziguli ezinomdlavuza we-canal canal ongaphendulanga ekwelashweni kwangaphambilini (i-refractory) futhi isakaze kwezinye izindawo emzimbeni (metastatic). I-Immunotherapy enama-antibody monoclonal, njenge-nivolumab ne-ipilimumab, ingasiza amasosha omzimba ukuthi ahlasele umdlavuza, futhi ingaphazamisa ikhono lamangqamuzana e-tumor ukukhula nokukhula.

Indawo: izindawo ezingama-42

I-Nivolumab ne-Ipilimumab ekwelapheni iziguli ezine-HIV ezihlobene nokubuyela emuva noma ukubuyisela emuva i-Classical Hodgkin Lymphoma noma ama-Tumors aqinile aMetastatic noma awanakususwa ngokuhlinzwa

Lesi sigaba sokuhlolwa kwesigaba sokuqala sihlola imiphumela emibi kanye nomthamo omuhle kakhulu we-nivolumab lapho unikezwa nge-ipilimumab ekwelapheni iziguli ezine-human immunodeficiency virus (HIV) ezihambisana ne-classical Hodgkin lymphoma ebuyile ngemuva kwesikhathi sokwenza ngcono noma engaphenduli ekwelashweni, noma izicubu eziqinile zisakazekele kwezinye izindawo emzimbeni noma azikwazi ukususwa ngokuhlinzwa. I-Immunotherapy enama-antibody monoclonal, njenge-ipilimumab ne-nivolumab, ingasiza amasosha omzimba ukuthi ahlasele umdlavuza, futhi ingaphazamisa ikhono lamangqamuzana e-tumor ukukhula nokukhula. I-Ipilimumab i-antibody esebenza ngokumelene ne-molecule ebizwa nge-cytotoxic T-lymphocyte antigen 4 (CTLA-4). I-CTLA-4 ilawula ingxenye yamasosha akho omzimba ngokuyivala. I-Nivolumab uhlobo lwe-antibody ecaciselwe ukufa komuntu okuhleliwe 1 (PD-1), iphrotheni elibhekene nokucekelwa phansi kwamaseli omzimba. Ukunikeza i-ipilimumab nge-nivolumab kungasebenza kangcono ekwelapheni iziguli ezine-HIV ezihambisana ne-classical Hodgkin lymphoma noma izicubu eziqinile uma kuqhathaniswa ne-ipilimumab ene-nivolumab iyodwa.

Indawo: izindawo ezingama-28

Isifundo se-XmAb®20717 kuzihloko ezinamaThumba aQinisekile aQinisiwe aKhethiwe

Lesi yisigaba 1, umthamo omningi, ocwaningweni lokukhuphuka kwedosi ukuchaza i-MTD / RD nohlobo lwe-XmAb20717, ukuchaza ukuphepha nokubekezelelana, ukuhlola i-PK kanye ne-immunogenicity, nokuhlola kuqala umsebenzi wokulwa nesimila weXmAb20717 ezifundweni ezikhethiwe izimila eziqinile ezithuthukile.

Indawo: izindawo eziyi-15

Ucwaningo lwe-Immun-therapy Study lokuphenya ukuphepha nokusebenza kweNivolumab, kanye neNivolumab Combination Therapy kumaThumba ahlobene ne-Virus

Inhloso yalolu cwaningo ukuphenya ukuphepha nokusebenza kwe-nivolumab, kanye ne-nivolumab therapy therapy, ukwelapha iziguli ezinamathumba ahambisana negciwane. Amagciwane athile aziwa ukuthi adlala indima ekwakheni isimila kanye nasekukhuleni. Lolu cwaningo luzophenya ngemiphumela yemishanguzo yocwaningo, ezigulini ezinalezi zinhlobo zezicubu: - Umdlavuza we-Anal canal-Awusabhalisi lolu hlobo lwesimila - Umdlavuza wesibeletho - I-Epstein Barr Virus (EBV) umdlavuza omuhle wesisu-Awusabhalisi lokhu uhlobo lwesimila - Umdlavuza Wamangqamuzana kaMerkel - Umdlavuza wePenile-Awusabhaliseli lolu hlobo lwesimila - Umdlavuza wesitho sangasese sowesifazane kanye nowomuntu obizwa nge-vulvar-Awusabhalisi lolu hlobo lwesimila - Umdlavuza weNasopharyngeal - Awusalubhalisi lolu hlobo lwesimila - Umdlavuza weNhloko Nentamo - Awusalubhalisi lolu hlobo lwesimila

Indawo: izindawo eziyi-10

Ukufundwa kwePembrolizumab (MK-3475) kubahlanganyeli abanezidumbu eziqinile ezithuthukile (MK-3475-158 / KEYNOTE-158)

Kulolu cwaningo, ababambiqhaza abanezinhlobo eziningi zamathumba aqinile (angenakulinganiswa kanye / noma we-metastatic) aqhubekele phambili ekwelashweni okujwayelekile kokunakekelwa azophathwa nge-pembrolizumab.

Indawo: izindawo eziyi-8

I-High-Dose-Rate Brachytherapy kanye neChemotherapy ekwelapheni iziguli ezine-Rectal Rectal noma i-Residual Rectal yangakini noma i-Residual Cancer Elawulwa Ukuphathwa Okungasebenzi

Lesi sigaba sokuhlolwa kwesilingo sihlola imiphumela emibi kanye nomthamo omuhle kakhulu we-high-dose-rate-brachytherapy lapho unikezwa kanye ne-chemotherapy ekwelapheni iziguli ezinomdlavuza we-rectal noma we-anal obuyile noma obi kakhulu futhi ongeke welashwe ngokuhlinzwa. I-Brachytherapy, eyaziwa nangokuthi ukwelashwa ngemisebe kwangaphakathi, isebenzisa izinto ezinemisebe efakwa ngqo ku-tumor noma eduze kwayo ukubulala amangqamuzana e-tumor. I-high-dose-rate (HDR) brachytherapy isebenzisa okokusebenza okukhipha imisebe ukuletha umthamo omkhulu wemisebe ngesikhathi esifushane esihlahleni. Ingase futhi ithumele imisebe emincane ezicutshini eziseduze ezinempilo futhi inganciphisa ubungozi bemiphumela emibi. Izidakamizwa ezisetshenziselwa ukwelashwa ngamakhemikhali, njenge-capecitabine ne-fluorouracil, zisebenza ngezindlela ezehlukene ukunqanda ukukhula kwamangqamuzana ama-tumor, kungaba ngokubulala amaseli, ngokuwavimba ekuhlukaniseni, noma ngokuwavimba ekusabalaleni.

Indawo: izindawo ezi-6

I-Pembrolizumab ekwelapheni iziguli ezinomdlavuza we-Metastatic noma Wendawo Othuthukile Ongasuswa Ngokuhlinzwa

Lesi sigaba sesivivinyo sesi-II sihlola ukuthi ipembrolizumab isebenza kahle kanjani ekwelapheni iziguli ezinomdlavuza wesilonda osusabalele kwezinye izindawo emzimbeni noma osuke usuka endaweni yayo yokuqala yokukhula waya ezicutshini eziseduze noma kuma-lymph node futhi awukwazi ukususwa ngokuhlinzwa. I-Immunotherapy enama-antibody monoclonal, njenge-pembrolizumab, ingasiza amasosha omzimba ukuthi ahlasele umdlavuza, futhi ingaphazamisa amandla amangqamuzana e-tumor ukuthi akhule futhi asabalale.

Indawo: izindawo ezi-5

Ukuhlinzwa Ukwelapha Iziguli Nge-Early Stage Anal Canal noma i-Perianal Cancer ne-HIV Positive

Lesi sigaba sesibili sokuhlolwa kwesivivinyo sokwelashwa ekwelapheni iziguli ezinomdlavuza we-anal canal noma we-perianal omncane futhi ongakasakazeki ngokujulile ezicutshini kanye ne-human immunodeficiency virus (HIV). Ukuhlinzwa kwasendaweni kungaba ukwelashwa okuphephile okunemiphumela emibi embalwa kunokuhlinzwa okukhulu noma imisebe kanye nokwelashwa ngamakhemikhali.

Indawo: izindawo ezi-5

Isivivinyo Sokuthola Nokuphenya I-Dose Ephephile Yento Entsha (i-BI 754091) Yeziguli Ezinamathumba Aqinile

Inhloso enkulu yengxenye yokwenyuka komthamo wesivivinyo ukucacisa ukuphepha nokubekezeleleka, nokunquma iMosisi Ebekezelela Ukukhuluphala kanye / noma i-Phase 2 Dose (RP2D) Ephakanyisiwe ye-BI 754091 ngesisekelo seziguli ezinomkhawulo wethamo ubuthi (i-DLTs) ezigulini ezinokulimala okuqinile okukhethiwe okuthuthukile. Ukuphepha nokubekezelela kuzohlolwa ngokuqapha ukwenzeka kwemicimbi emibi (ama-AEs), ama-AE abucayi (SAE), kanye nokungajwayelekile kwemingcele yelabhorethri, kanye nezinguquko ezibonakalisweni ezibalulekile. Izinhloso zesibili ukunqunywa kwephrofayili ye-PK ye-BI 754091 ngemuva kokulinganisa okukodwa nokuningi kwe-BI 754091, kanye nokuhlolwa kokuqala komsebenzi we-antitumour. Engxenyeni yesilingo yokwandiswa komthamo, izinhloso eziyinhloko ukuqhubeka nokuhlola ukuphepha, ukusebenza kahle, iphrofayili ye-PK,

Indawo: izindawo ezi-3

Ama-Radiosurgery e-Stereotactic ekwelapheni iziguli ezinezifo ze-Oligometastatic

Lesi sigaba sesivivinyo sesi-II sifundisisa ukuthi i-stereotactic radiosurgery isebenza kanjani ekwelapheni iziguli ezinomdlavuza ezisabalalele ezindaweni ezi-5 noma ezimbalwa emzimbeni futhi zibandakanya izitho ezi-3 noma ezimbalwa (isifo se-oligometastatic). I-radiosurgery ye-stereotactic, eyaziwa nangokuthi i-stereotactic therapy yomzimba, iyindlela yokwelapha ekhethekile yemisebe eletha umthamo owodwa, ophezulu wemisebe ngqo esihlahleni futhi ingabulala amangqamuzana amaningi we-tumor futhi idale umonakalo omncane kwizicubu ezijwayelekile.

Indawo: izindawo ezi-3

Ucwaningo lwe-INCMGA00012 ku-squamous Carcinoma we-Can Canal Okulandela i-Platinum-based Chemotherapy (POD1UM-202)

Inhloso yalolu cwaningo ukuhlola ukusebenza kwe-INCMGA00012 kubahlanganyeli abane-carcinoma e-advanced can or metastatic squamous carcinoma ye-canal anal (SCAC) abaye bathuthuka ngemuva kwe-chemotherapy ese-platinum.

Indawo: 4 izindawo

I-Artesunate ekwelapheni iziguli ezine-High-Grade Anal Intraepithelial Neoplasia

Lesi sigaba sesivivinyo sihlola imiphumela emibi kanye nomthamo omuhle we-artesunate ekwelapheni iziguli ezine-grade ephezulu ye-anal intraepithelial neoplasia. I-anal intraepithelial neoplasia ngamaseli angaphambi kwesikhathi angahle abe noma angabi ngumdlavuza ngokuzayo. Izinguquko eziningi eziholela kumdlavuza zidalwa yi-human papillomavirus (HPV). I-Artesunate ingabulala amaseli atheleleke nge-HPV.

Indawo: izindawo ezi-2

Ucwaningo lwe-LY3434172, i-PD-1 ne-PD-L1 Bispecific Antibody, ku-Advanced Cancer

Inhloso enkulu yalolu cwaningo ukuhlola ukuphepha nokubekezeleleka komuthi ocwaningwayo i-LY3434172, i-PD-1 / PD-L1 bispecific antibody, kubahlanganyeli abanezicubu eziqinile ezithuthukile.

Indawo: MD Anderson Cancer Center, eHouston, Texas

I-SL-279252 (PD1-Fc-OX40L) ezifundweni ezinama-Advanced Solid Tumors noma amaLymphomas

Lesi yisigaba sokuqala sokuqala kwelebuli lomuntu, evulekile, enezikhungo eziningi, ukukhuphuka komthamo kanye nocwaningo lokukhulisa umthamo ukuhlola ukuphepha, ukubekezelelana, i-PK, umsebenzi wokulwa nesimila kanye nemiphumela ye-pharmacodynamic ye-SL-279252 ezifundweni ezinamathumba aqinile athuthukile noma ama-lymphomas .

Indawo: MD Anderson Cancer Center, eHouston, Texas

I-LET-IMPT kanye ne-Chemotherapy ejwayelekile ekwelapheni iziguli ezineSiteji Esisha Esitholakele I-III I-Can Canal Squamous Cell Cancer

Isivivinyo sesigaba II sihlola imiphumela emibi ye-LET-IMPT kanye ne-chemotherapy ejwayelekile, nokuthi basebenza kahle kanjani ekwelapheni iziguli ezinesifo somdlavuza esivele sisanda kutholakala I-III canal squamous cell cancer. I-LET-IMPT wuhlobo lokwelashwa ngemisebe olusebenzisa amandla amakhulu we-proton “beamlets” “ukupenda” umthamo wemisebe kulokho okubhekiswe kukho futhi kungasiza ekubulaleni amangqamuzana ezimila futhi kunciphise izimila. Ukunikeza i-LET-IMPT kanye ne-chemotherapy ejwayelekile kungasebenza kangcono ekwelapheni iziguli ezinomdlavuza we-canal squamous cell.

Indawo: MD Anderson Cancer Center, eHouston, Texas

I-VGX-3100 ne-Electroporation ekwelapheni iziguli ezine-HIV-Positive High-Grade Anal izilonda

Lokhu kuhlolwa kwesigaba II kucwaninga ukuthi i-human papillomavirus (HPV) deoxyribonucleic acid (DNA) i-plasmids yokugoma yokwelapha i-VGX-3100 (VGX-3100) nomsebenzi we-electroporation ekwelapheni iziguli ezine-human immunodeficiency virus (HIV) - izilonda ezisezingeni eliphakeme. Imithi yokugoma eyenziwe nge-DNA ingasiza umzimba ukuthi wakhe amasosha omzimba ngempumelelo ukubulala amangqamuzana ezimila. I-Electroporation isiza ama-pores kumaseli omzimba wakho ukuba athathe umuthi ukuqinisa ukuphendula kwamasosha akho omzimba. Ukunikeza i-VGX-3100 kanye ne-electroporation ndawonye kungasebenza kangcono ekwelapheni iziguli ezinezilonda zangasese ezisezingeni eliphakeme.

Indawo: izindawo ezi-2

I-DNA Plasmid-encoding Interleukin-12 / HPV DNA Plasmids Therapeutic Vaccine INO-3112 neDurvalumab ekwelapheni iziguli ezinomdlavuza ohlanganisiwe we-Recurrent noma we-Metastatic Human Papillomavirus.

Lesi sigaba sesivivinyo sesi-II sihlola ukuthi i-deoxyribonucleic acid (DNA) plasmid-encoding interleukin-12 / human papillomavirus (HPV) DNA plasmids yokugoma yokwelapha i-INO-3112 kanye ne-durvalumab isebenza ekwelapheni iziguli ezinomdlavuza we-papillomavirus womuntu obuyile noma osabalalele kwezinye izindawo emzimbeni. Imithi yokugoma eyenziwe ngegciwane eliguqulwe izakhi zofuzo ingasiza umzimba ukwakha impendulo ephumelelayo yokuzivikela ukuze kubulale amangqamuzana ezimila. I-Immunotherapy enama-antibody monoclonal, njenge-durvalumab, ingasiza amasosha omzimba ukuba ahlasele umdlavuza, futhi ingaphazamisa ikhono lamangqamuzana e-tumor ukukhula nokukhula. Ukunikeza i-DNA plasmid-encoding interleukin-12 / HPV DNA plasmids umuthi wokugoma i-INO-3112 kanye ne-durvalumab kungasebenza kangcono ekwelapheni iziguli ezinomdlavuza we-papillomavirus wabantu.

Indawo: MD Anderson Cancer Center, eHouston, Texas

M7824 kuzihloko ezine-HPV Associated Malignancies

Ingemuva: E-United States, unyaka ngamunye kunezigameko ezingaphezu kwama-30,000 zomdlavuza ohlobene ne-human papillomavirus (HPV). Eminye yale mdlavuza ayelapheki futhi ayithuthukiswa yimithi ejwayelekile. Abaphenyi bafuna ukubona ukuthi umuthi omusha i-M7824, oqonde futhi uvimbe indlela evimbela amasosha omzimba ekulweni nomdlavuza ngempumelelo anganciphisa izicubu kubantu abanomdlavuza othile we-HPV. Izinhloso: Ukubona ukuthi umuthi i-M7824 ubangela ukuthi izicubu zinciphe. Ukufaneleka: Abantu abadala abaneminyaka engu-18 nangaphezulu abanomdlavuza ohambisana nokutheleleka kwe-HPV. Idizayini: Ababambiqhaza bazohlolwa ngomlando wezokwelapha kanye nokuhlolwa komzimba. Bazobuyekeza izimpawu zabo nokuthi benza kanjani imisebenzi ejwayelekile. Bazoba nokuskena komzimba. Bazonikeza amasampula egazi nomchamo. Bazoba nesampula lezicubu zabo zesimila ezithathwe uma eyodwa ingatholakali. Abahlanganyeli bazoba ne-electrocardiogram yokuhlola inhliziyo yabo. Ngemuva kwalokho bazothola umuthi ocwaningwayo ngepayipi elincanyana emthanjeni wengalo. Ababambiqhaza bazothola umuthi njalo emavikini ama-2 izikhathi ezingama-26 (unyaka ongu-1). Lesi isifundo esingu-1. Ngemuva kwesifundo, ababambiqhaza bazobhekwa kodwa ngeke basisebenzise lesi sidakamizwa. Uma isimo sabo siba sibi kakhulu, bazoqala enye inkambo ngalo muthi. Le nqubo ingaphindwa kaningi ngangokunokwenzeka. Ukwelashwa kuzoma uma umbambiqhaza enemiphumela emibi noma umuthi uyeka ukusebenza. Kuwo wonke ucwaningo, ababambiqhaza bazophinda okunye noma konke ukuhlolwa kokuhlolwa. Ngemuva kokuthi ababambiqhaza beyeke ukuthatha lo muthi, bazovakashelwa futhi bese bephinda ezinye izivivinyo zokuhlola. Bazothola izingcingo ezilandelwayo ngezikhathi ezithile. ... Ngemuva kwalokho bazothola umuthi ocwaningwayo ngepayipi elincanyana emthanjeni wengalo. Ababambiqhaza bazothola umuthi njalo emavikini ama-2 izikhathi ezingama-26 (unyaka ongu-1). Lesi isifundo esingu-1. Ngemuva kwesifundo, ababambiqhaza bazobhekwa kodwa ngeke basisebenzise lesi sidakamizwa. Uma isimo sabo siba sibi kakhulu, bazoqala enye inkambo ngalo muthi. Le nqubo ingaphindwa kaningi ngangokunokwenzeka. Ukwelashwa kuzoma uma umbambiqhaza enemiphumela emibi noma umuthi uyeka ukusebenza. Kuwo wonke ucwaningo, ababambiqhaza bazophinda okunye noma konke ukuhlolwa kokuhlolwa. Ngemuva kokuthi ababambiqhaza beyeke ukuthatha lo muthi, bazovakashelwa futhi bese bephinda ezinye izivivinyo zokuhlola. Bazothola izingcingo ezilandelwayo ngezikhathi ezithile. ... Ngemuva kwalokho bazothola umuthi ocwaningwayo ngepayipi elincanyana emthanjeni wengalo. Ababambiqhaza bazothola umuthi njalo emavikini ama-2 izikhathi ezingama-26 (unyaka ongu-1). Lesi isifundo esingu-1. Ngemuva kwesifundo, ababambiqhaza bazobhekwa kodwa ngeke basisebenzise lesi sidakamizwa. Uma isimo sabo siba sibi kakhulu, bazoqala enye inkambo ngalo muthi. Le nqubo ingaphindwa kaningi ngangokunokwenzeka. Ukwelashwa kuzoma uma umbambiqhaza enemiphumela emibi noma umuthi uyeka ukusebenza. Kuwo wonke ucwaningo, ababambiqhaza bazophinda okunye noma konke ukuhlolwa kokuhlolwa. Ngemuva kokuthi ababambiqhaza beyeke ukuthatha lo muthi, bazovakashelwa futhi bese bephinda ezinye izivivinyo zokuhlola. Bazothola izingcingo ezilandelwayo ngezikhathi ezithile. ... ababambiqhaza bazobhekwa kodwa ngeke basebenzise umuthi ocwaningwayo. Uma isimo sabo siba sibi kakhulu, bazoqala enye inkambo ngalo muthi. Le nqubo ingaphindwa kaningi ngangokunokwenzeka. Ukwelashwa kuzoma uma umbambiqhaza enemiphumela emibi noma umuthi uyeka ukusebenza. Kuwo wonke ucwaningo, ababambiqhaza bazophinda okunye noma konke ukuhlolwa kokuhlolwa. Ngemuva kokuthi ababambiqhaza beyeke ukuthatha lo muthi, bazovakashelwa futhi bese bephinda ezinye izivivinyo zokuhlola. Bazothola izingcingo ezilandelwayo ngezikhathi ezithile. ... ababambiqhaza bazobhekwa kodwa ngeke basebenzise umuthi ocwaningwayo. Uma isimo sabo siba sibi kakhulu, bazoqala enye inkambo ngalo muthi. Le nqubo ingaphindwa kaningi ngangokunokwenzeka. Ukwelashwa kuzoma uma umbambiqhaza enemiphumela emibi noma umuthi uyeka ukusebenza. Kuwo wonke ucwaningo, ababambiqhaza bazophinda okunye noma konke ukuhlolwa kokuhlolwa. Ngemuva kokuthi ababambiqhaza beyeke ukuthatha lo muthi, bazovakashelwa futhi bese bephinda ezinye izivivinyo zokuhlola. Bazothola izingcingo ezilandelwayo ngezikhathi ezithile. ... Ngemuva kokuthi ababambiqhaza beyeke ukuthatha lo muthi, bazovakashelwa futhi bese bephinda ezinye izivivinyo zokuhlola. Bazothola izingcingo ezilandelwayo ngezikhathi ezithile. ... Ngemuva kokuthi ababambiqhaza beyeke ukuthatha lo muthi, bazovakashelwa futhi bese bephinda ezinye izivivinyo zokuhlola. Bazothola izingcingo ezilandelwayo ngezikhathi ezithile. ...

Indawo: Izikhungo Zikazwelonke Zempilo Clinical Centre, eBethesda, eMaryland

I-MnSOD Mimetic BMX-001 ekwelapheni Iziguli Ezinomdlavuza Wokuhlinzwa Othola Ukwelashwa Kwemisebe kanye neChemotherapy

Lesi sigaba sokuhlolwa kwesigaba sokuqala sifundisisa umthamo omuhle kakhulu we-MnSOD mimetic BMX-001 ukunciphisa imiphumela emibi ezigulini ezinomdlavuza we-anal ezelashwa ngemisebe kanye ne-chemotherapy. Izidakamizwa ze-Chemoprotective, njenge-BMX-001, zingavikela amaseli ajwayelekile emiphumeleni emibi ye-chemotherapy ngenkathi ithuthukisa ukubulawa kwe-tumor.

Indawo: Isikhungo Sezokwelapha sase-University of Nebraska, e-Omaha, eNebraska

I-Atezolizumab neBevacizumab ekwelapheni iziguli ezinezicubu eziqinile

Lesi sigaba sesivivinyo sesi-II sihlola ukuthi i-atezolizumab ne-bevacizumab zisebenza kahle kanjani ekwelapheni iziguli ezinamathumba angaqinile. I-Immunotherapy enama-antibody monoclonal, njenge-atezolizumab ne-bevacizumab, ingasiza amasosha omzimba ukuthi ahlasele umdlavuza, futhi ingaphazamisa amandla amangqamuzana wesimila ukukhula nokukhula.

Indawo: MD Anderson Cancer Center, eHouston, Texas

Ukwelashwa Kokugoma kanye neCyclophosphamide Ekwelapheni Iziguli ezine-HLA-A * 02 Positive Relapsed, Refractory, or Metastatic HPV16-Related Oropharyngeal, Cervical, or Anal Cancer

Lesi sigaba sicwaninga ngemiphumela emibi kanye nomthamo omuhle we-HPV16-E711-19 womuthi wokugomela i-nanomer DPX-E7 nokubona ukuthi usebenza kahle kanjani uma unikezwa kanye ne-cyclophosphamide ekwelapheni iziguli ezine-HLA-A * 02, i-papillomavirus yabantu 16 ( I-HPV16) ehlobene ne-oropharyngeal, umdlavuza womlomo wesibeletho, noma owangemuva obuyile, awuphenduli ekwelashweni, noma usabalele kwezinye izingxenye zomzimba. Imithi yokugoma eyenziwe ngegciwane eliguqulwe izakhi zofuzo ingasiza umzimba ukwakha impendulo ephumelelayo yokuzivikela ukuze kubulale amangqamuzana ezimila. Izidakamizwa ezisetshenziselwa ukwelashwa ngamakhemikhali, njenge-cyclophosphamide, zisebenza ngezindlela ezehlukene ukunqanda ukukhula kwamangqamuzana ezinzwa, kungaba ngokubulala amaseli, ngokuwavimba ekuhlukaniseni, noma ngokuwavimba ekusabalaleni. Ukunikeza umuthi wokugoma i-HPV16-E711-19 nanomer DPX-E7 kanye ne-cyclophosphamide kungasebenza kangcono ekwelapheni iziguli ezine-oropharyngeal ehlobene ne-HPV16,

Indawo: Dana-Farber Cancer Institute, eBoston, eMassachusetts

INivolumab ne-Ipilimumab ekwelapheni iziguli ezinamathumba angajwayelekile

Lesi sigaba sesibili sokuhlolwa kwesivivinyo se-nivolumab ne-ipilimumab ekwelapheni iziguli ezinamathumba angavamile. I-Immunotherapy enama-antibody monoclonal, njenge-nivolumab ne-ipilimumab, ingasiza amasosha omzimba ukuthi ahlasele umdlavuza, futhi ingaphazamisa ikhono lamangqamuzana e-tumor ukukhula nokukhula. Lokhu kuhlolwa kubhalisa ababambiqhaza bamaqoqo alandelayo ngokuya ngesimo: 1. Izicubu ze-Epithelial ze-nasal cavity, sinuses, nasopharynx: A) I-squamous cell carcinoma enezinhlobonhlobo zomgodi wamakhala, ama-sinus, ne-nasopharynx ne-trachea (ngaphandle komdlavuza we-laryngeal, nasopharyngeal [NPC] , kanye ne-squamous cell carcinoma yekhanda nentamo [SCCHN]) B) I-Adenocarcinoma kanye nokuhlukahluka komgodi wamakhala, ama-sinus, ne-nasopharynx (kuvaliwe kuya ku-07/27/2018) 2. Izicubu ze-Epithelial zezindlala ezinkulu zamathe (zivaliwe zanda ngo-03) / 20/2018) 3. Izinduna zohlobo lwe-salivary gland ekhanda nasentanyeni, udebe, umphimbo, isisu, uqhoqhoqho namaphaphu, isifuba nenye indawo (kuvaliwe ukuze kube yisiqoqelalwazi) 4. I-carcinoma engaziwa yomgudu wamathumbu (GI) 5. I-Adenocarcinoma enezinhlobonhlobo zamathumbu amancane (avaliwe ukuze athole okwengeziwe) 05/10/2018) 6. I-squamous cell carcinoma enezinhlobo ezihlukile zepheshana le-GI (isisu esincane amathumbu, ikholoni, i-rectum, amanyikwe) (kuvaliwe kuya ku-10/17/2018) 7. I-Fibromixoma kanye ne-low grade mucinous adenocarcinoma (pseudomixoma peritonei) ye isithasiselo ne-ovary (kuvaliwe kuya ku-03/20/2018) 8. Izicubu ezivamile zepancreatic ezibandakanya i-acinar cell carcinoma, i-mucinous cystadenocarcinoma noma i-serous cystadenocarcinoma. I-Pancreatic adenocarcinoma ayifanelekile i-9.I-Intrahepatic cholangiocarcinoma (ivaliwe ukuhlangana ngo-03/20/2018) 10. Izicubu ze-Extrahepatic cholangiocarcinoma ne-bile duct (zivaliwe ukuze zande ngo-03/20/2018) 11. I-Sarcomatoid carcinoma yamaphaphu 12. I-bronchoalveolar carcinoma lung. Lesi simo manje sesibizwa nangokuthi i-adenocarcinoma in situ, i-adenocarcinoma encane, i-adenocarcinoma epidic, noma i-muenous adenocarcinoma 13. Izicubu ezingenayo i-epithelial ye-ovary: A) Isimila seGerm cell se-ovary B) Isigaxa se-Mullerian ixubene ne-adenosarcoma (ivaliwe ukwengeza ngo-03/30/2018) 14. Isigaxa se-Trophoblastic: A) I-Choriocarcinoma (ivaliwe ngo-04/15/2019) 15. I-Transitional cell carcinoma ngaphandle kwaleyo yezinso, okhalweni, i-ureter, noma isinye (ivalwe ngo-04 / 15/2019) 16. Isimila seseli lama-testes kanye nezicubu zegciwane le-extragonadal: Izicubu ze-Apocrine / extramammary Isifo sikaPaget 40. I-Peritoneal mesothelioma 41. I-Basal cell carcinoma 42. Sula umdlavuza wesibeletho weseli 43. I-Esthenioneuroblastoma 44. I-endometrial carcinosarcoma (izicubu ezixubene ezixubene zeMullerian) (ivaliwe yanda) 45. Sula umdlavuza wesibeletho wesibeletho se-endometrial 46. Sula iseli umdlavuza we-ovari 47. Isifo se-Gestational trophoblastic disease (GTD) 48. Umdlavuza we-Gallbladder 49. I-carcinoma yeseli elincane le-ovary, uhlobo lwe-hypercalcemic 50. I-PD-L1 ikhulise izicubu 51. I-Angiosarcoma 52. I-high-grade neuroendocrine carcinoma (i-pancreatic neuroendocrine tumor [PNET] kufanele babhalise ku-Cohort 22; ama-prostatic neuroendocrine carcinomas kufanele abhalise ku-Cohort 53). Umdlavuza wamaphaphu weseli omncane awufanelekile 53. Umdlavuza wesifo samathumbu esincane esivela ekwelashweni (t-SCNC) Sula umdlavuza wamangqamuzana omlomo wesibeletho 43. Esthenioneuroblastoma 44. I-Endometrial carcinosarcoma (izicubu ezixubene ezixubene nezicubu zikaMullerian) (zivaliwe zanda) 45. Sula umdlavuza wesibeletho wesibeletho se-endometrial 46. Sula umdlavuza wama-ovari weseli 47. Isifo se-Gestational trophoblastic disease (GTD) 48. Umdlavuza we-Gallbladder 49. Omncane i-cell carcinoma ye-ovary, uhlobo lwe-hypercalcemic 50. I-PD-L1 ikhulise izicubu 51. I-Angiosarcoma 52. I-high-grade neuroendocrine carcinoma (i-pancreatic neuroendocrine tumor [PNET] kufanele ibhaliswe kuqoqo 22; i-prostatic neuroendocrine carcinomas kufanele ibhaliswe ku-Cohort 53). Umdlavuza wamaphaphu weseli omncane awufanelekile 53. Umdlavuza wesifo samathumbu esincane esivela ekwelashweni (t-SCNC) Sula umdlavuza wamangqamuzana omlomo wesibeletho 43. Esthenioneuroblastoma 44. I-Endometrial carcinosarcoma (izicubu ezixubene ezixubene nezicubu zikaMullerian) (zivaliwe zanda) 45. Sula umdlavuza wesibeletho wesibeletho se-endometrial 46. Sula umdlavuza wama-ovari weseli 47. Isifo se-Gestational trophoblastic disease (GTD) 48. Umdlavuza we-Gallbladder 49. Omncane i-cell carcinoma ye-ovary, uhlobo lwe-hypercalcemic 50. I-PD-L1 ikhulise izicubu 51. I-Angiosarcoma 52. I-high-grade neuroendocrine carcinoma (i-pancreatic neuroendocrine tumor [PNET] kufanele ibhaliswe kuqoqo 22; i-prostatic neuroendocrine carcinomas kufanele ibhaliswe ku-Cohort 53). Umdlavuza wamaphaphu weseli omncane awufanelekile 53. Umdlavuza wesifo samathumbu esincane esivela ekwelashweni (t-SCNC) Sula umdlavuza wama-ovari weseli 47. Isifo se-Gestational trophoblastic disease (GTD) 48. Umdlavuza we-Gallbladder 49. I-carcinoma yeseli elincane le-ovary, uhlobo lwe-hypercalcemic 50. I-PD-L1 ikhulise izicubu 51. I-Angiosarcoma 52. I-high-grade neuroendocrine carcinoma (i-pancreatic neuroendocrine tumor [PNET ] kufanele babhalise kuCohort 22; i-prostatic neuroendocrine carcinomas kufanele ibhalise ku-Cohort 53). Umdlavuza wamaphaphu weseli omncane awufanelekile 53. Umdlavuza wesifo samathumbu esincane esivela ekwelashweni (t-SCNC) Sula umdlavuza wama-ovari weseli 47. Isifo se-Gestational trophoblastic (GTD) 48. Umdlavuza we-Gallbladder 49. I-carcinoma yeseli elincane le-ovary, uhlobo lwe-hypercalcemic 50. I-PD-L1 ikhulise izicubu 51. I-Angiosarcoma 52. I-high-grade neuroendocrine carcinoma (i-pancreatic neuroendocrine tumor [PNET ] kufanele babhalise kuCohort 22; i-prostatic neuroendocrine carcinomas kufanele ibhalise ku-Cohort 53). Umdlavuza wamaphaphu weseli omncane awufanelekile 53. Umdlavuza wesifo samathumbu esincane esivela ekwelashweni (t-SCNC) i-prostatic neuroendocrine carcinomas kufanele ibhaliswe kuqoqo 53). Umdlavuza wamaphaphu weseli omncane awufanelekile 53. Umdlavuza wesifo samathumbu esincane esivela ekwelashweni (t-SCNC) i-prostatic neuroendocrine carcinomas kufanele ibhaliswe kuqoqo 53). Umdlavuza wamaphaphu weseli omncane awufanelekile 53. Umdlavuza ovela ekwelashweni kwamaseli amancane we-neuroendocrine prostate (t-SCNC)

Indawo: izindawo ezingama-878